iiinova — where your digital self keeps evolving

Deirdre Dunne @dunnedeirdre.bsky.social · 19/10/2025

Today’s Annals of Oncology and ESMO Open Concomitant publications are available online: www.annalsofoncology.org/concomitant @myesmo.bsky.social #ESMO25

031

Deirdre Dunne @dunnedeirdre.bsky.social · 18/10/2025

The First Annals of Oncology and ESMO Open Concomitant publications are available online: www.annalsofoncology.org/concomitant @myesmo.bsky.social #ESMO25

020

Reposted by Deirdre Dunne

Cancer Trials Ireland @cancertrialsie.bsky.social · 17/10/2025

Update from the #POSITIVE trial at #ESMO25 - 71-month follow-up showed no increase in recurrence among women who paused treatment to conceive, offering important reassurance for patients and clinicians 👏 🇮🇪 participated, with CTI as national sponsor and Prof Janice Walsh as NLI. #BreastCancer

032

Reposted by Deirdre Dunne

International Society of Liquid Biopsy @islb.info · 12/04/2025

🚨 ESMO’s New Global Guidelines for Molecular Tumor Boards (MTBs) 🧬💻 Published in Annals of Oncology, this comprehensive special article by the @myESMO Precision Oncology Working Group delivers international recommendations to standardize MTB structure, quality, and function in clinical practice.

031

Reposted by Deirdre Dunne

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 15/04/2025

New research in Annals of Oncology shows that a breath-based diagnostic tool—an “electronic nose”—is getting surprisingly close to clinical reality. #lungcancer

medpagetoday.com

Sniffing Out Lung Cancer: Breath Analyzer Moves Closer to Clinical Use

So-called eNose achieves 80-90% performance level for lung cancer detection

021

Reposted by Deirdre Dunne

GBG @gbg.de · 23/04/2025

📢 New in Annals of Oncology: Final survival results from the #PENELOPEB trial: Palbociclib vs placebo in high-risk HR+/HER2- breast cancer after neoadjuvant chemo. Full paper: www.annalsofoncology.org/article/S092...

011

Reposted by Deirdre Dunne

European Organisation for Research and Treatment of Cancer @eortc.org · 31/05/2025

📢 Delighted to share a new publication in Annals of Oncology. PEACE III is the first major Phase III trial to combine an ARPI with radiopharmaceutical that showed statistical significance in meeting the primary endpoint.https://ow.ly/SH8K50W1Zct @silkegillessen.bsky.social

011

Reposted by Deirdre Dunne

European Society for Radiotherapy and Oncology (ESTRO) @estroradiotherapy.bsky.social · 04/06/2025

Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study, published in Annals of Oncology. 👉 Read it before your patients: bit.ly/43NzBfO

011

Reposted by Deirdre Dunne

Precision Oncology News @preconcnews.bsky.social · 07/06/2025

Potential solid tumor indications for MRD continue to pile up, including new cervical cancer data presented at ASCO and simultaneously published in Annals of Oncology.

precisionmedicineonline.com

ASCO Data on Personalis Assay Suggests Role for ctDNA MRD Testing in Cervical Cancer

012

Reposted by Deirdre Dunne

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 11/06/2025

👉 Asia Pacific’s oncology spotlight is on you. Submit your abstract for ESMO Asia 2025 by 12 August. Get published in Annals of Oncology and connect with top experts in Singapore, 5–7 December. Your research. Your impact. #ESMOAsia25 🔗 buff.ly/ycEGK9a

021

Deirdre Dunne @dunnedeirdre.bsky.social · 20/03/2025

An exciting first day of the ESMO Sarcoma and Rare Cancers congress with the launch of ESMO Rare Cancers! Congratulations to the Editorial team on reaching this important milestone. The inaugural issue is online: www.esmorarecancers.org/current

030

Reposted by Deirdre Dunne

Jon Lim, FRCP PhD @drjonlim.bsky.social · 11/12/2024

Gutted not to be Geneva 🇨🇭 for #ESMOImmuno24 in person this year 🥹. If you are presenting your work at #ESMOImmuno24, and potentially looking for a home for your research work, please consider submitting to our ESMO IOTECH journal: 🔗 esmoiotech.org

253

Deirdre Dunne @dunnedeirdre.bsky.social · 04/12/2024

📢👏👏👏👏👏THANKS TO REFEREES 2024: The Editor-in-Chief and Associate Editors of Annals of Oncology would like to extend their sincere appreciation to all those who have worked as referees for the journal. www.sciencedirect.com/science/arti... #ESMO

sciencedirect.com

THANKS TO REFEREES 2024

050

Deirdre Dunne @dunnedeirdre.bsky.social · 04/12/2024

New Annals of Oncology article in press: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial www.sciencedirect.com/science/arti... #ESMO

030

Deirdre Dunne @dunnedeirdre.bsky.social · 04/12/2024

📖 #AnnalsOfOncology #DYK Alongside Annals of Oncology, ESMO’s portfolio includes ESMO Open, Immuno-Oncology and Technology, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology & ESMO Rare Cancers to provide comprehensive insights across #Oncology 🔗 ow.ly/exiT50UgvZl

020

Deirdre Dunne @dunnedeirdre.bsky.social · 26/11/2024

I'm delighted to announce that ESMO Rare Cancers is now open for submissions! For more information on our aims & scope, please have a look at the introductory Editorial by the Co-Editors-in-Chief #ESMO #Oncology www.esmorarecancers.org/article/S305...

0155

Deirdre Dunne @dunnedeirdre.bsky.social · 25/11/2024

📖 #AnnalsOfOncology #MilestonesMonday: In 2008 Annals_ of Oncology became the official journal of the Japanese Society of Medical Oncology expanding its global influence and matching the society’s global expansion. #ESMO 🔗 ow.ly/9LCT50U8U9f

020

Deirdre Dunne @dunnedeirdre.bsky.social · 24/11/2024

📖 @Annals of Oncology marks 35 years with Prof. David Kerr, Editor-in-Chief (2000-2009). He reflects on the journal’s growth, challenges, and offers advice for emerging researchers. Read the full interview 🔗 ow.ly/Osug50UbMfe

ow.ly

Annals of Oncology 35th Anniversary - Interview with Prof. David Kerr

Prof. Kerr discusses the challenges he faced, the journal’s evolution, and its growing impact on the field

020

Deirdre Dunne @dunnedeirdre.bsky.social · 22/11/2024

👉 Watch Prof. Gietema, Dr. Trama, Dr. Valverde & Prof. Girard discuss how collaboration drives better outcomes for rare cancer patients. Submit your abstract for ESMO Sarcoma and Rare Cancers 2025 by 7 Jan & join the conversation! #ESMORareCancers25 🔗 ow.ly/bxph50Ua6zJ

031

Deirdre Dunne @dunnedeirdre.bsky.social · 22/11/2024

📖 To mark the 35th anniversary of Annals of Oncology, Prof. Cavalli, founding Editor-in-Chief (1989-2000), reflects on the journal’s origins, challenges, and its impact on advancing oncology. #ESMO 🔗 ow.ly/uC6R50UbLJE

020

Deirdre Dunne @dunnedeirdre.bsky.social · 21/11/2024

📖 Have you read "Exosome-based liquid biopsies in cancer: opportunities and challenges", one of Annals of Oncology’s top-cited papers of 2023? #CancerResearch #AnnalsOfOncology 🔗 ow.ly/9AYe50U7MNP

020

Deirdre Dunne @dunnedeirdre.bsky.social · 21/11/2024

📖 To mark 35 years of Annals of Oncology, putting a 2023 top-cited paper in the spotlight: "High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types." #AnnalsOfOncology 🔗 ow.ly/pbE650U7MPt

020

Deirdre Dunne @dunnedeirdre.bsky.social · 19/11/2024

Congratulations to IOTECH Editor in Chief Prof John Haanen on receiving the 2024 KNAW Bob Pinedo Cancer Care Award. www.esmoiotech.org #ESMO

esmoiotech.org

DEFINE_ME

030

Deirdre Dunne @dunnedeirdre.bsky.social · 19/11/2024

#ESMOImmuno24: 🚨 Last Chance to Save on Registration 🚨 Exciting times ahead! Late-breaking abstract authors-titles are now online! 👉 Head to the programme to see the science you can look forward to and register today! Hope to see you there! 🔗https://ow.ly/QvNu50U483r

020

Deirdre Dunne @dunnedeirdre.bsky.social · 19/11/2024

👉 Discover how to implement the ESMO Guidelines in real-world clinical scenarios and contribute to a richer learning experience by submitting your questions to the experts. 🔗 ow.ly/3v8h50U67lG

062

Deirdre Dunne @dunnedeirdre.bsky.social · 19/11/2024

Annals of Oncology received its first impact factor in 1994, a key achievement in #oncology publishing. 3 decades later the IF stands at 56.7, ranking 4th in oncology www.sciencedirect.com/journal/anna...

020

Deirdre Dunne @dunnedeirdre.bsky.social · 19/11/2024

📖 #AnnalsOfOncology #DYK In December 1990 Annals of Oncology published its first ESMO Congress abstract book, featuring 481 abstracts from 25 countries. 🔗 ow.ly/EZc450U6NfO

000

Deirdre Dunne @dunnedeirdre.bsky.social · 19/11/2024

📖 #AnnalsOfOncology #MilestonesMonday: In 2000, David Kerr succeeded Franco Cavalli to become the second Editor-in-Chief of Annals of Oncology shaping its next decade of impactful publications. ow.ly/NiT850U6N8i

020

Deirdre Dunne @dunnedeirdre.bsky.social · 18/11/2024

Check out this new study published in ESMO Open looking at clinical outcomes of early stage #TripleNegativeBreastCancer after neoadjuvant chemotherapy according to #HER2low status☆ www.sciencedirect.com/science/arti... @ptarantinomd.bsky.social

0113

Deirdre Dunne @dunnedeirdre.bsky.social · 18/11/2024

Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy - published in ESMO Open #precisionmedicine www.esmoopen.com/article/S205...

110

Deirdre Dunne @dunnedeirdre.bsky.social · 18/11/2024

🎧Article of the month: listen to the new podcast in which Annals of Oncology Editor-in-Chief Tom Powles discusses the ENGOT-en11/GOG-3053/KEYNOTE-B21 trial with Dr Toon Van Gorp of the Leuven Cancer Institute, Belgium. soundcloud.com/esmo-podcast...

031

Deirdre Dunne @dunnedeirdre.bsky.social · 18/11/2024

New Annals of Oncology article in press: A phase III randomized trial on the addition of a contact x-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial annalsofoncology.org/retrieve/pii...

020

Deirdre Dunne @dunnedeirdre.bsky.social · 18/11/2024

📖 #AnnalsOfOncology #MilestonesMonday: The very first issue of Annals of Oncology was published in January 1990 with Franco Cavalli as founding Editor-in-Chief. Since then, it’s been a key resource for Oncology Research and practice worldwide. 🔗 ow.ly/wHRu50U6MWV

000

Deirdre Dunne @dunnedeirdre.bsky.social · 18/11/2024

📖 ESMO invites you to mark Annals of Oncology’s 35th Anniversary by exploring significant milestones with the Milestones Monday series, the #DYK post series, exclusive interviews with Editors-in-Chief, and the 2023 most-cited papers 🔗 ow.ly/8rwR50U6a4t

000

Deirdre Dunne @dunnedeirdre.bsky.social · 18/11/2024

📢New guidelines in press - Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up linkinghub.elsevier.com/retrieve/pii...

000

Deirdre Dunne @dunnedeirdre.bsky.social · 18/11/2024

Stay up to date with the very latest from Annals of Oncology. Register for free to receive content and issue alerts by e-mail bit.ly/2WfW9Cb or subscribe to our RSS bit.ly/2yRH9Cp

000

Deirdre Dunne @dunnedeirdre.bsky.social · 18/11/2024

I’m thrilled to announce the launch of ESMO Rare Cancers! This new journal aims to enhance the understanding and management of rare malignancies. Join us in sharing impactful research and improving patient outcomes. Learn more: spkl.io/8283

000

Deirdre Dunne @dunnedeirdre.bsky.social · 18/11/2024

Discover the latest in real world data and digital oncology in ESMO Real World Data and Digital Oncology. Read our groundbreaking article, 'Equitable access to oncology clinical trials: harnessing technology to reduce geographic disparities' spkl.io/6012fuqYm

010

Deirdre Dunne @dunnedeirdre.bsky.social · 18/11/2024

What are pragmatic clinical trials? New commentary in ESMO Real World Data and Digital Oncology explores how they use #realworld data to generate evidence. ➡️ spkl.io/6019fRzXH

000

Deirdre Dunne @dunnedeirdre.bsky.social · 18/11/2024

Check out this month’s highlights from the European Society of Medical Oncology titles! www.esmojournals.org

000